[
    {
        "id": 7439,
        "drug_name": "KIMMTRAK (tebentafusp-tebn)",
        "clinical_trial_id": "NCT03070392",
        "has_trial_insight_page": 0,
        "indication": "Uveal melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-26",
        "link": "https:\/\/www.benzinga.com\/node\/25228985",
        "note": "Approved January 26, 2022. ",
        "company_entity_id": 880,
        "company_ticker": "IMCR",
        "company_name": "Immunocore Holdings plc",
        "company_price": "61.2300",
        "company_change": 0.27,
        "company_percent_change": 0.44,
        "company_optionable": 1,
        "company_number_of_shares": 48088346,
        "price_change_sparkline": [
            [
                72.29,
                1706677200
            ],
            [
                75.21,
                1706763600
            ],
            [
                73.74,
                1706850000
            ],
            [
                73.8,
                1707109200
            ],
            [
                75.2,
                1707195600
            ],
            [
                75.36,
                1707282000
            ],
            [
                74.93,
                1707368400
            ],
            [
                74.61,
                1707454800
            ],
            [
                74.52,
                1707714000
            ],
            [
                71.99,
                1707800400
            ],
            [
                71.65,
                1707886800
            ],
            [
                70.5,
                1707973200
            ],
            [
                69.99,
                1708059600
            ],
            [
                69.09,
                1708405200
            ],
            [
                70.24,
                1708491600
            ],
            [
                69.43,
                1708578000
            ],
            [
                69.86,
                1708664400
            ],
            [
                70.97,
                1708923600
            ],
            [
                70.45,
                1709010000
            ],
            [
                69.21,
                1709096400
            ],
            [
                67.22,
                1709182800
            ],
            [
                67.41,
                1709269200
            ],
            [
                65.37,
                1709528400
            ],
            [
                65.06,
                1709614800
            ],
            [
                63.97,
                1709701200
            ],
            [
                63.03,
                1709787600
            ],
            [
                61.61,
                1709874000
            ],
            [
                60.96,
                1710129600
            ],
            [
                61.23,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6365,
        "drug_name": "Faricimab (RG7716)",
        "clinical_trial_id": "NCT03622580",
        "has_trial_insight_page": 0,
        "indication": "Diabetic Macular Edema",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-28",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220128005009\/en\/",
        "note": "FDA Approval announced January 28, 2022.",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8920,
        "drug_name": "VONVENDI",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Type 3 von Willebrand Disease (VWD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-31",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220131005214\/en\/",
        "note": "Approved January 31, 2022. ",
        "company_entity_id": 751,
        "company_ticker": "TAK",
        "company_name": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1\/2 of a share of)",
        "company_price": "14.3700",
        "company_change": -0.19999999999999996,
        "company_percent_change": -1.37,
        "company_optionable": 1,
        "company_number_of_shares": 3137776702,
        "price_change_sparkline": [
            [
                14.6,
                1706677200
            ],
            [
                14.38,
                1706763600
            ],
            [
                14.28,
                1706850000
            ],
            [
                13.92,
                1707109200
            ],
            [
                14.16,
                1707195600
            ],
            [
                14.18,
                1707282000
            ],
            [
                14,
                1707368400
            ],
            [
                14.24,
                1707454800
            ],
            [
                14.31,
                1707714000
            ],
            [
                14.34,
                1707800400
            ],
            [
                14.54,
                1707886800
            ],
            [
                14.42,
                1707973200
            ],
            [
                14.62,
                1708059600
            ],
            [
                14.82,
                1708405200
            ],
            [
                14.74,
                1708491600
            ],
            [
                14.64,
                1708578000
            ],
            [
                14.62,
                1708664400
            ],
            [
                14.81,
                1708923600
            ],
            [
                14.84,
                1709010000
            ],
            [
                14.65,
                1709096400
            ],
            [
                14.59,
                1709182800
            ],
            [
                14.56,
                1709269200
            ],
            [
                14.48,
                1709528400
            ],
            [
                14.4,
                1709614800
            ],
            [
                14.69,
                1709701200
            ],
            [
                14.86,
                1709787600
            ],
            [
                14.77,
                1709874000
            ],
            [
                14.57,
                1710129600
            ],
            [
                14.37,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8917,
        "drug_name": "Vabysmo (faricimab-svoa)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Wet age-related macular degeneration (nAMD) and diabetic macular edema (DME)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-31",
        "link": "https:\/\/ml-eu.globenewswire.com\/Resource\/Download\/f1e71507-4c4d-45f5-a748-ce0bc930a5a9",
        "note": "Approved January 31, 2022. ",
        "company_entity_id": 536,
        "company_ticker": "RHHBY",
        "company_name": "Roche Holding AG ADR",
        "company_price": "35.1500",
        "company_change": 0.54,
        "company_percent_change": 1.56,
        "company_optionable": 0,
        "company_number_of_shares": 6389213336,
        "price_change_sparkline": [
            [
                35.14,
                1706677200
            ],
            [
                34.32,
                1706763600
            ],
            [
                33.95,
                1706850000
            ],
            [
                33.16,
                1707109200
            ],
            [
                33.27,
                1707195600
            ],
            [
                32.55,
                1707282000
            ],
            [
                32.1,
                1707368400
            ],
            [
                32.31,
                1707454800
            ],
            [
                32.6,
                1707714000
            ],
            [
                32.13,
                1707800400
            ],
            [
                32.02,
                1707886800
            ],
            [
                32.1,
                1707973200
            ],
            [
                32.28,
                1708059600
            ],
            [
                32.74,
                1708405200
            ],
            [
                32.91,
                1708491600
            ],
            [
                32.49,
                1708578000
            ],
            [
                32.96,
                1708664400
            ],
            [
                32.52,
                1708923600
            ],
            [
                33.03,
                1709010000
            ],
            [
                32.93,
                1709096400
            ],
            [
                32.73,
                1709182800
            ],
            [
                33.08,
                1709269200
            ],
            [
                32.88,
                1709528400
            ],
            [
                33.15,
                1709614800
            ],
            [
                33.47,
                1709701200
            ],
            [
                33.77,
                1709787600
            ],
            [
                33.9,
                1709874000
            ],
            [
                34.61,
                1710129600
            ],
            [
                35.15,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6404,
        "drug_name": "SPIKEVAX (mRNA-1273)",
        "clinical_trial_id": "NCT04405076",
        "has_trial_insight_page": 0,
        "indication": "COVID-19 vaccine ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-01-31",
        "link": "https:\/\/www.accesswire.com\/686397\/Moderna-Receives-Full-US-FDA-Approval-for-COVID-19-Vaccine-Spikevax",
        "note": "Full approval January 31, 2022. ",
        "company_entity_id": 618,
        "company_ticker": "MRNA",
        "company_name": "Moderna Inc.",
        "company_price": "110.4300",
        "company_change": -1.55,
        "company_percent_change": -1.38,
        "company_optionable": 1,
        "company_number_of_shares": 382073208,
        "price_change_sparkline": [
            [
                101.05,
                1706677200
            ],
            [
                99.02,
                1706763600
            ],
            [
                97.5,
                1706850000
            ],
            [
                95.49,
                1707109200
            ],
            [
                100.03,
                1707195600
            ],
            [
                99.3,
                1707282000
            ],
            [
                93.66,
                1707368400
            ],
            [
                87.41,
                1707454800
            ],
            [
                89,
                1707714000
            ],
            [
                85.37,
                1707800400
            ],
            [
                85.95,
                1707886800
            ],
            [
                91.14,
                1707973200
            ],
            [
                88.37,
                1708059600
            ],
            [
                86.99,
                1708405200
            ],
            [
                87.59,
                1708491600
            ],
            [
                99.44,
                1708578000
            ],
            [
                96.46,
                1708664400
            ],
            [
                94.02,
                1708923600
            ],
            [
                96.2,
                1709010000
            ],
            [
                97.48,
                1709096400
            ],
            [
                92.24,
                1709182800
            ],
            [
                95.06,
                1709269200
            ],
            [
                96,
                1709528400
            ],
            [
                95.56,
                1709614800
            ],
            [
                98.1,
                1709701200
            ],
            [
                99.48,
                1709787600
            ],
            [
                103.03,
                1709874000
            ],
            [
                111.98,
                1710129600
            ],
            [
                110.43,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5711,
        "drug_name": "Cabenuva (cabotegravir + rilpivirine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220118006212\/en\/",
        "note": "Approved February 1, 2022. ",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 5711,
        "drug_name": "Cabenuva (cabotegravir + rilpivirine)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "HIV",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-01",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220118006212\/en\/",
        "note": "Approved February 1, 2022. ",
        "company_entity_id": 387,
        "company_ticker": "PFE",
        "company_name": "Pfizer Inc.",
        "company_price": "28.0100",
        "company_change": -0.36,
        "company_percent_change": -1.27,
        "company_optionable": 1,
        "company_number_of_shares": 5646778425,
        "price_change_sparkline": [
            [
                27.08,
                1706677200
            ],
            [
                27.29,
                1706763600
            ],
            [
                26.93,
                1706850000
            ],
            [
                26.57,
                1707109200
            ],
            [
                27.5,
                1707195600
            ],
            [
                27.56,
                1707282000
            ],
            [
                27.57,
                1707368400
            ],
            [
                27.56,
                1707454800
            ],
            [
                27.66,
                1707714000
            ],
            [
                26.97,
                1707800400
            ],
            [
                27.11,
                1707886800
            ],
            [
                27.51,
                1707973200
            ],
            [
                27.62,
                1708059600
            ],
            [
                27.59,
                1708405200
            ],
            [
                27.67,
                1708491600
            ],
            [
                27.55,
                1708578000
            ],
            [
                27.76,
                1708664400
            ],
            [
                27.18,
                1708923600
            ],
            [
                26.89,
                1709010000
            ],
            [
                27.04,
                1709096400
            ],
            [
                26.56,
                1709182800
            ],
            [
                26.59,
                1709269200
            ],
            [
                25.89,
                1709528400
            ],
            [
                26.08,
                1709614800
            ],
            [
                27.19,
                1709701200
            ],
            [
                26.79,
                1709787600
            ],
            [
                27.22,
                1709874000
            ],
            [
                28.37,
                1710129600
            ],
            [
                28.01,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8936,
        "drug_name": "Cyclosporine Ophthalmic Emulsion (generic restasis)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Dry eye disease",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-03",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/viatris-is-first-to-receive-fda-approval-of-generic-restasis-cyclosporine-ophthalmic-emulsion-0-05-to-treat-dry-eye-disease-301475343.html",
        "note": "Approved February 3, 2022. ",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7393,
        "drug_name": "Bebtelovimab (LY-CoV1404) and Sotrovimab (VIR-7831 \/ GSK4182136) - (BLAZE-4)",
        "clinical_trial_id": "NCT04634409",
        "has_trial_insight_page": 1,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-11",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19-301480923.html",
        "note": "EUA granted by FDA February 11, 2022.",
        "company_entity_id": 379,
        "company_ticker": "GSK",
        "company_name": "GSK plc American Depositary Shares (Each representing two)",
        "company_price": "43.2700",
        "company_change": 0.35,
        "company_percent_change": 0.82,
        "company_optionable": 1,
        "company_number_of_shares": 2058516719,
        "price_change_sparkline": [
            [
                39.0637603938206,
                1706677200
            ],
            [
                40.2424083367376,
                1706763600
            ],
            [
                40.3315497777986,
                1706850000
            ],
            [
                41.1734411655964,
                1707109200
            ],
            [
                41.3517240477183,
                1707195600
            ],
            [
                41.6191483709012,
                1707282000
            ],
            [
                41.4210562796546,
                1707368400
            ],
            [
                41.5101977207156,
                1707454800
            ],
            [
                40.67821093748,
                1707714000
            ],
            [
                40.9951582834745,
                1707800400
            ],
            [
                41.40124707053,
                1707886800
            ],
            [
                41.371533256843,
                1707973200
            ],
            [
                41.5399115344025,
                1708059600
            ],
            [
                41.6191483709012,
                1708405200
            ],
            [
                41.5399115344025,
                1708491600
            ],
            [
                42.16,
                1708578000
            ],
            [
                42.22,
                1708664400
            ],
            [
                42.34,
                1708923600
            ],
            [
                42.38,
                1709010000
            ],
            [
                42.34,
                1709096400
            ],
            [
                41.9,
                1709182800
            ],
            [
                42.03,
                1709269200
            ],
            [
                42.44,
                1709528400
            ],
            [
                42.6,
                1709614800
            ],
            [
                42.62,
                1709701200
            ],
            [
                43.58,
                1709787600
            ],
            [
                43.14,
                1709874000
            ],
            [
                42.92,
                1710129600
            ],
            [
                43.27,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7393,
        "drug_name": "Bebtelovimab (LY-CoV1404) and Sotrovimab (VIR-7831 \/ GSK4182136) - (BLAZE-4)",
        "clinical_trial_id": "NCT04634409",
        "has_trial_insight_page": 1,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-11",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19-301480923.html",
        "note": "EUA granted by FDA February 11, 2022.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7393,
        "drug_name": "Bebtelovimab (LY-CoV1404) and Sotrovimab (VIR-7831 \/ GSK4182136) - (BLAZE-4)",
        "clinical_trial_id": "NCT04634409",
        "has_trial_insight_page": 1,
        "indication": "COVID-19 antibody",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-11",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/lillys-bebtelovimab-receives-emergency-use-authorization-for-the-treatment-of-mild-to-moderate-covid-19-301480923.html",
        "note": "EUA granted by FDA February 11, 2022.",
        "company_entity_id": 708,
        "company_ticker": "VIR",
        "company_name": "Vir Biotechnology Inc.",
        "company_price": "10.7300",
        "company_change": -0.6699999999999999,
        "company_percent_change": -5.88,
        "company_optionable": 1,
        "company_number_of_shares": 135032268,
        "price_change_sparkline": [
            [
                9.4,
                1706677200
            ],
            [
                9.12,
                1706763600
            ],
            [
                8.67,
                1706850000
            ],
            [
                8.6,
                1707109200
            ],
            [
                8.99,
                1707195600
            ],
            [
                9.06,
                1707282000
            ],
            [
                9.23,
                1707368400
            ],
            [
                9.29,
                1707454800
            ],
            [
                9.74,
                1707714000
            ],
            [
                8.85,
                1707800400
            ],
            [
                9.79,
                1707886800
            ],
            [
                10.31,
                1707973200
            ],
            [
                10.25,
                1708059600
            ],
            [
                10.23,
                1708405200
            ],
            [
                10.11,
                1708491600
            ],
            [
                10.3,
                1708578000
            ],
            [
                11.53,
                1708664400
            ],
            [
                11.9,
                1708923600
            ],
            [
                11.43,
                1709010000
            ],
            [
                11.6,
                1709096400
            ],
            [
                11.24,
                1709182800
            ],
            [
                11.24,
                1709269200
            ],
            [
                11.19,
                1709528400
            ],
            [
                10.88,
                1709614800
            ],
            [
                10.92,
                1709701200
            ],
            [
                11.26,
                1709787600
            ],
            [
                11.36,
                1709874000
            ],
            [
                11.4,
                1710129600
            ],
            [
                10.73,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 3892,
        "drug_name": "Mitapivat (AG-348)",
        "clinical_trial_id": "NCT03559699",
        "has_trial_insight_page": 0,
        "indication": "Pyruvate kinase deficiency",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-17",
        "link": "https:\/\/www.globenewswire.com\/news-release\/2022\/02\/17\/2387542\/0\/en\/Agios-Announces-FDA-Approval-of-PYRUKYND-mitapivat-as-First-Disease-Modifying-Therapy-for-Hemolytic-Anemia-in-Adults-with-Pyruvate-Kinase-Deficiency.html",
        "note": "Approved February 17, 2022.",
        "company_entity_id": 23,
        "company_ticker": "AGIO",
        "company_name": "Agios Pharmaceuticals Inc.",
        "company_price": "30.2900",
        "company_change": -0.51,
        "company_percent_change": -1.66,
        "company_optionable": 1,
        "company_number_of_shares": 56194847,
        "price_change_sparkline": [
            [
                22.62,
                1706677200
            ],
            [
                22.96,
                1706763600
            ],
            [
                23.09,
                1706850000
            ],
            [
                23.73,
                1707109200
            ],
            [
                24.15,
                1707195600
            ],
            [
                23.69,
                1707282000
            ],
            [
                24.18,
                1707368400
            ],
            [
                25.14,
                1707454800
            ],
            [
                25.88,
                1707714000
            ],
            [
                25.15,
                1707800400
            ],
            [
                25.9,
                1707886800
            ],
            [
                26.8,
                1707973200
            ],
            [
                26.51,
                1708059600
            ],
            [
                27.1,
                1708405200
            ],
            [
                26.8,
                1708491600
            ],
            [
                29.78,
                1708578000
            ],
            [
                32.99,
                1708664400
            ],
            [
                32.87,
                1708923600
            ],
            [
                34.81,
                1709010000
            ],
            [
                33.67,
                1709096400
            ],
            [
                32.32,
                1709182800
            ],
            [
                32.27,
                1709269200
            ],
            [
                32.17,
                1709528400
            ],
            [
                31.37,
                1709614800
            ],
            [
                31.79,
                1709701200
            ],
            [
                31.37,
                1709787600
            ],
            [
                31.29,
                1709874000
            ],
            [
                30.8,
                1710129600
            ],
            [
                30.29,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7401,
        "drug_name": "JARDIANCE (empagliflozin)",
        "clinical_trial_id": "NCT03057951",
        "has_trial_insight_page": 0,
        "indication": "Heart failure with preserved Ejection Fraction (HFpEF)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-24",
        "link": "https:\/\/www.boehringer-ingelheim.us\/press-release\/us-fda-approves-jardiance-empagliflozin-treat-adults-heart-failure-regardless-left",
        "note": "Approved February 24, 2022.",
        "company_entity_id": 382,
        "company_ticker": "LLY",
        "company_name": "Eli Lilly and Company",
        "company_price": "754.9500",
        "company_change": 20.58,
        "company_percent_change": 2.8,
        "company_optionable": 1,
        "company_number_of_shares": 950164452,
        "price_change_sparkline": [
            [
                644.503643637706,
                1706677200
            ],
            [
                659.298247188938,
                1706763600
            ],
            [
                666.505874560051,
                1706850000
            ],
            [
                704.989812947364,
                1707109200
            ],
            [
                703.821817930162,
                1707195600
            ],
            [
                724.13694493877,
                1707282000
            ],
            [
                734.41929423551,
                1707368400
            ],
            [
                738.891617036422,
                1707454800
            ],
            [
                735.996586651903,
                1707714000
            ],
            [
                741.696801650387,
                1707800400
            ],
            [
                757.31,
                1707886800
            ],
            [
                757.78,
                1707973200
            ],
            [
                782.06,
                1708059600
            ],
            [
                755.66,
                1708405200
            ],
            [
                745.91,
                1708491600
            ],
            [
                769.64,
                1708578000
            ],
            [
                769.54,
                1708664400
            ],
            [
                771.92,
                1708923600
            ],
            [
                765,
                1709010000
            ],
            [
                757.64,
                1709096400
            ],
            [
                753.68,
                1709182800
            ],
            [
                782.12,
                1709269200
            ],
            [
                792.28,
                1709528400
            ],
            [
                777.59,
                1709614800
            ],
            [
                779.77,
                1709701200
            ],
            [
                780.16,
                1709787600
            ],
            [
                762.14,
                1709874000
            ],
            [
                734.37,
                1710129600
            ],
            [
                754.95,
                1710216000
            ]
        ],
        "statuses": [
            {
                "label": "Breakthrough Therapy Designation (BTD)",
                "abbreviation": "BTD",
                "description": "Breakthrough Therapy Designation (BTD)",
                "description_html": "<p>Breakthrough Therapy Designation (BTD)<\/p>\n"
            }
        ]
    },
    {
        "id": 6697,
        "drug_name": "CARVYKTI (ciltacabtagene autoleucel)",
        "clinical_trial_id": "NCT03548207",
        "has_trial_insight_page": 0,
        "indication": "Multiple myeloma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-02-28",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220228006246\/en\/",
        "note": "Approved February 28, 2022.",
        "company_entity_id": 765,
        "company_ticker": "LEGN",
        "company_name": "Legend Biotech Corporation",
        "company_price": "65.1300",
        "company_change": -0.06000000000000005,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 165067240,
        "price_change_sparkline": [
            [
                55.06,
                1706677200
            ],
            [
                56.22,
                1706763600
            ],
            [
                55.76,
                1706850000
            ],
            [
                58.46,
                1707109200
            ],
            [
                59.41,
                1707195600
            ],
            [
                58.62,
                1707282000
            ],
            [
                58.72,
                1707368400
            ],
            [
                60.97,
                1707454800
            ],
            [
                60.48,
                1707714000
            ],
            [
                58.67,
                1707800400
            ],
            [
                57.83,
                1707886800
            ],
            [
                57.05,
                1707973200
            ],
            [
                58.11,
                1708059600
            ],
            [
                60.1,
                1708405200
            ],
            [
                59.83,
                1708491600
            ],
            [
                61.72,
                1708578000
            ],
            [
                66.1,
                1708664400
            ],
            [
                67,
                1708923600
            ],
            [
                69.99,
                1709010000
            ],
            [
                67.78,
                1709096400
            ],
            [
                65.16,
                1709182800
            ],
            [
                65.53,
                1709269200
            ],
            [
                64.51,
                1709528400
            ],
            [
                63.66,
                1709614800
            ],
            [
                63.78,
                1709701200
            ],
            [
                64.22,
                1709787600
            ],
            [
                63.25,
                1709874000
            ],
            [
                65.19,
                1710129600
            ],
            [
                65.13,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9029,
        "drug_name": "Opdivo (nivolumab) plus Chemotherapy",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Non-small cell lung cancer (NSCLC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-04",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220301006264\/en\/",
        "note": "Approved March 4, 2022. ",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4649,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "NCT02032823",
        "has_trial_insight_page": 0,
        "indication": "BRCAm HER2-negative breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-11",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html",
        "note": "Approved March 11, 2022. ",
        "company_entity_id": 374,
        "company_ticker": "AZN",
        "company_name": "AstraZeneca PLC",
        "company_price": "67.4000",
        "company_change": -0.27,
        "company_percent_change": -0.4,
        "company_optionable": 1,
        "company_number_of_shares": 3100378676,
        "price_change_sparkline": [
            [
                65.6319311986485,
                1706677200
            ],
            [
                65.8387545112493,
                1706763600
            ],
            [
                64.647058281502,
                1706850000
            ],
            [
                64.1546218229287,
                1707109200
            ],
            [
                66.0258803655072,
                1707195600
            ],
            [
                65.5432926361053,
                1707282000
            ],
            [
                62.5591276971512,
                1707368400
            ],
            [
                61.3181878215465,
                1707454800
            ],
            [
                60.4810458419719,
                1707714000
            ],
            [
                60.1067941334562,
                1707800400
            ],
            [
                60.7272640712585,
                1707886800
            ],
            [
                61.8894141134915,
                1707973200
            ],
            [
                63.2977823850111,
                1708059600
            ],
            [
                64.056134531214,
                1708405200
            ],
            [
                64.1053781770713,
                1708491600
            ],
            [
                64.13,
                1708578000
            ],
            [
                65.83,
                1708664400
            ],
            [
                65.93,
                1708923600
            ],
            [
                66.33,
                1709010000
            ],
            [
                65.35,
                1709096400
            ],
            [
                64.16,
                1709182800
            ],
            [
                64.6,
                1709269200
            ],
            [
                64.79,
                1709528400
            ],
            [
                64.81,
                1709614800
            ],
            [
                65.27,
                1709701200
            ],
            [
                66.19,
                1709787600
            ],
            [
                66.5,
                1709874000
            ],
            [
                67.67,
                1710129600
            ],
            [
                67.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4649,
        "drug_name": "LYNPARZA (olaparib)",
        "clinical_trial_id": "NCT02032823",
        "has_trial_insight_page": 0,
        "indication": "BRCAm HER2-negative breast cancer",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-11",
        "link": "https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2022\/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html",
        "note": "Approved March 11, 2022. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 9102,
        "drug_name": "Breyna (Symbicort generic)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Asthma or chronic obstructive pulmonary disease (COPD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-15",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/viatris-inc-announces-receipt-of-the-first-fda-approval-for-generic-version-of-symbicort-inhalation-aerosol-breyna-budesonide-and-formoterol-fumarate-dihydrate-inhalation-aerosol-in-partnership-with-kindeva-301503954.html",
        "note": "Approved March 15, 2022. ",
        "company_entity_id": 851,
        "company_ticker": "VTRS",
        "company_name": "Viatris Inc.",
        "company_price": "12.0600",
        "company_change": 0.09,
        "company_percent_change": 0.75,
        "company_optionable": 1,
        "company_number_of_shares": 1187569149,
        "price_change_sparkline": [
            [
                11.6559127625202,
                1706677200
            ],
            [
                11.754943457189,
                1706763600
            ],
            [
                11.7351373182553,
                1706850000
            ],
            [
                11.4677544426494,
                1707109200
            ],
            [
                11.7747495961228,
                1707195600
            ],
            [
                11.6262035541195,
                1707282000
            ],
            [
                11.4479483037157,
                1707368400
            ],
            [
                11.5667851373183,
                1707454800
            ],
            [
                11.8341680129241,
                1707714000
            ],
            [
                11.8539741518578,
                1707800400
            ],
            [
                11.9530048465267,
                1707886800
            ],
            [
                12.6957350565428,
                1707973200
            ],
            [
                12.933408723748,
                1708059600
            ],
            [
                13.1116639741519,
                1708405200
            ],
            [
                13.1314701130856,
                1708491600
            ],
            [
                13.2305008077544,
                1708578000
            ],
            [
                13.3988529886914,
                1708664400
            ],
            [
                13.2998222940226,
                1708923600
            ],
            [
                13.101760904685,
                1709010000
            ],
            [
                12.1708723747981,
                1709096400
            ],
            [
                12.2500969305331,
                1709182800
            ],
            [
                12.4679644588045,
                1709269200
            ],
            [
                12.2401938610662,
                1709528400
            ],
            [
                12.1609693053312,
                1709614800
            ],
            [
                12.0817447495961,
                1709701200
            ],
            [
                12.2104846526656,
                1709787600
            ],
            [
                12.26,
                1709874000
            ],
            [
                11.97,
                1710129600
            ],
            [
                12.06,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 7418,
        "drug_name": "RINVOQ (Upadacitinib)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "Ulcerative Colitis",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-16",
        "link": "https:\/\/www.prnewswire.com\/news-releases\/rinvoq-upadacitinib-receives-fda-approval-for-the-treatment-of-adults-with-moderately-to-severely-active-ulcerative-colitis-301504545.html",
        "note": "Approved March 16, 2022. ",
        "company_entity_id": 369,
        "company_ticker": "ABBV",
        "company_name": "AbbVie Inc.",
        "company_price": "180.9200",
        "company_change": 1.29,
        "company_percent_change": 0.72,
        "company_optionable": 1,
        "company_number_of_shares": 1766473359,
        "price_change_sparkline": [
            [
                164.4,
                1706677200
            ],
            [
                167.59,
                1706763600
            ],
            [
                168.67,
                1706850000
            ],
            [
                171.26,
                1707109200
            ],
            [
                173.29,
                1707195600
            ],
            [
                175.01,
                1707282000
            ],
            [
                174.79,
                1707368400
            ],
            [
                174.08,
                1707454800
            ],
            [
                173.07,
                1707714000
            ],
            [
                173.29,
                1707800400
            ],
            [
                174.42,
                1707886800
            ],
            [
                176.59,
                1707973200
            ],
            [
                177.49,
                1708059600
            ],
            [
                175.75,
                1708405200
            ],
            [
                175.14,
                1708491600
            ],
            [
                176.75,
                1708578000
            ],
            [
                178.09,
                1708664400
            ],
            [
                178.81,
                1708923600
            ],
            [
                178.99,
                1709010000
            ],
            [
                178,
                1709096400
            ],
            [
                176.05,
                1709182800
            ],
            [
                178.91,
                1709269200
            ],
            [
                177.05,
                1709528400
            ],
            [
                179.16,
                1709614800
            ],
            [
                181.06,
                1709701200
            ],
            [
                180.57,
                1709787600
            ],
            [
                178.85,
                1709874000
            ],
            [
                179.63,
                1710129600
            ],
            [
                180.92,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 4012,
        "drug_name": "ZTALMY (ganaxolone)",
        "clinical_trial_id": "NCT03572933",
        "has_trial_insight_page": 0,
        "indication": "CDKL5 Deficiency Disorder (CDD)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220318005282\/en\/",
        "note": "Approved March 18, 2022. ",
        "company_entity_id": 202,
        "company_ticker": "MRNS",
        "company_name": "Marinus Pharmaceuticals Inc.",
        "company_price": "9.2800",
        "company_change": 0.8,
        "company_percent_change": 9.43,
        "company_optionable": 1,
        "company_number_of_shares": 54642580,
        "price_change_sparkline": [
            [
                9.74,
                1706677200
            ],
            [
                9.99,
                1706763600
            ],
            [
                9.98,
                1706850000
            ],
            [
                9.94,
                1707109200
            ],
            [
                10,
                1707195600
            ],
            [
                9.91,
                1707282000
            ],
            [
                9.99,
                1707368400
            ],
            [
                10.1,
                1707454800
            ],
            [
                10.21,
                1707714000
            ],
            [
                9.9,
                1707800400
            ],
            [
                10.01,
                1707886800
            ],
            [
                10,
                1707973200
            ],
            [
                9.96,
                1708059600
            ],
            [
                9.54,
                1708405200
            ],
            [
                9.75,
                1708491600
            ],
            [
                9.62,
                1708578000
            ],
            [
                9.77,
                1708664400
            ],
            [
                9.99,
                1708923600
            ],
            [
                10,
                1709010000
            ],
            [
                9.86,
                1709096400
            ],
            [
                9.5,
                1709182800
            ],
            [
                9.92,
                1709269200
            ],
            [
                9.54,
                1709528400
            ],
            [
                9.24,
                1709614800
            ],
            [
                9.03,
                1709701200
            ],
            [
                8.75,
                1709787600
            ],
            [
                8.85,
                1709874000
            ],
            [
                8.48,
                1710129600
            ],
            [
                9.28,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6326,
        "drug_name": "Opdualag (nivolumab and relatlimab-rmbw)",
        "clinical_trial_id": "NCT03470922",
        "has_trial_insight_page": 0,
        "indication": "Melanoma",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-18",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220304005561\/en\/",
        "note": "Approved March 18, 2022.",
        "company_entity_id": 376,
        "company_ticker": "BMY",
        "company_name": "Bristol-Myers Squibb Company",
        "company_price": "54.4000",
        "company_change": 0.04,
        "company_percent_change": 0.07,
        "company_optionable": 1,
        "company_number_of_shares": 2022193411,
        "price_change_sparkline": [
            [
                48.87,
                1706677200
            ],
            [
                48.67,
                1706763600
            ],
            [
                48.71,
                1706850000
            ],
            [
                47.98,
                1707109200
            ],
            [
                49.26,
                1707195600
            ],
            [
                48.64,
                1707282000
            ],
            [
                48.71,
                1707368400
            ],
            [
                49.81,
                1707454800
            ],
            [
                49.75,
                1707714000
            ],
            [
                48.71,
                1707800400
            ],
            [
                48.89,
                1707886800
            ],
            [
                49.44,
                1707973200
            ],
            [
                49.86,
                1708059600
            ],
            [
                49.86,
                1708405200
            ],
            [
                50.91,
                1708491600
            ],
            [
                51.33,
                1708578000
            ],
            [
                51.66,
                1708664400
            ],
            [
                50.52,
                1708923600
            ],
            [
                50.51,
                1709010000
            ],
            [
                50.92,
                1709096400
            ],
            [
                50.75,
                1709182800
            ],
            [
                50.89,
                1709269200
            ],
            [
                50.92,
                1709528400
            ],
            [
                51.82,
                1709614800
            ],
            [
                53.38,
                1709701200
            ],
            [
                53.28,
                1709787600
            ],
            [
                53.79,
                1709874000
            ],
            [
                54.36,
                1710129600
            ],
            [
                54.4,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 8119,
        "drug_name": "KEYTRUDA (pembrolizumab)",
        "clinical_trial_id": "",
        "has_trial_insight_page": 0,
        "indication": "MSI-H\/dMMR Advanced Endometrial Carcinoma ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-21",
        "link": "https:\/\/www.businesswire.com\/news\/home\/20220321005859\/en\/",
        "note": "Approved March 21, 2022. ",
        "company_entity_id": 383,
        "company_ticker": "MRK",
        "company_name": "Merck & Company Inc.",
        "company_price": "122.6600",
        "company_change": -0.10999999999999999,
        "company_percent_change": -0.08999999999999997,
        "company_optionable": 1,
        "company_number_of_shares": 2532643872,
        "price_change_sparkline": [
            [
                120.78,
                1706677200
            ],
            [
                126.38,
                1706763600
            ],
            [
                126.41,
                1706850000
            ],
            [
                126.18,
                1707109200
            ],
            [
                126.88,
                1707195600
            ],
            [
                127.47,
                1707282000
            ],
            [
                126.61,
                1707368400
            ],
            [
                125.45,
                1707454800
            ],
            [
                125.34,
                1707714000
            ],
            [
                125.43,
                1707800400
            ],
            [
                125.82,
                1707886800
            ],
            [
                126.54,
                1707973200
            ],
            [
                127.79,
                1708059600
            ],
            [
                127.37,
                1708405200
            ],
            [
                128.12,
                1708491600
            ],
            [
                129.26,
                1708578000
            ],
            [
                129.45,
                1708664400
            ],
            [
                128.84,
                1708923600
            ],
            [
                129.03,
                1709010000
            ],
            [
                128.19,
                1709096400
            ],
            [
                127.15,
                1709182800
            ],
            [
                126.96,
                1709269200
            ],
            [
                124.05,
                1709528400
            ],
            [
                122.83,
                1709614800
            ],
            [
                123.75,
                1709701200
            ],
            [
                123.99,
                1709787600
            ],
            [
                123.5,
                1709874000
            ],
            [
                122.77,
                1710129600
            ],
            [
                122.66,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 2347,
        "drug_name": "177Lu-PSMA-617",
        "clinical_trial_id": "NCT03511664",
        "has_trial_insight_page": 0,
        "indication": "Metastatic castration-resistant prostate cancer (mCRPC)",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-23",
        "link": "https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/215833s000lbl.pdf",
        "note": "Approved March 23, 2022. ",
        "company_entity_id": 386,
        "company_ticker": "NVS",
        "company_name": "Novartis AG",
        "company_price": "99.7700",
        "company_change": -1.6,
        "company_percent_change": -1.58,
        "company_optionable": 1,
        "company_number_of_shares": 2044033986,
        "price_change_sparkline": [
            [
                99.701426650332,
                1706677200
            ],
            [
                101.493681927897,
                1706763600
            ],
            [
                99.9423211768864,
                1706850000
            ],
            [
                99.701426650332,
                1707109200
            ],
            [
                99.9615927390107,
                1707195600
            ],
            [
                99.6917908692698,
                1707282000
            ],
            [
                97.6682768462129,
                1707368400
            ],
            [
                97.3502960711611,
                1707454800
            ],
            [
                96.8685070180523,
                1707714000
            ],
            [
                95.4520472019125,
                1707800400
            ],
            [
                95.4424114208503,
                1707886800
            ],
            [
                96.0012867224565,
                1707973200
            ],
            [
                96.5408904619384,
                1708059600
            ],
            [
                98.9787430706688,
                1708405200
            ],
            [
                98.824570573674,
                1708491600
            ],
            [
                99.0558293191662,
                1708578000
            ],
            [
                100.115765236006,
                1708664400
            ],
            [
                99.4894394669641,
                1708923600
            ],
            [
                99.3930816563424,
                1709010000
            ],
            [
                98.49695401756,
                1709096400
            ],
            [
                97.2924813847881,
                1709182800
            ],
            [
                98.3427815205652,
                1709269200
            ],
            [
                98.2560594910056,
                1709528400
            ],
            [
                98.3813246448139,
                1709614800
            ],
            [
                98.9016568221714,
                1709701200
            ],
            [
                99.93,
                1709787600
            ],
            [
                100.71,
                1709874000
            ],
            [
                101.37,
                1710129600
            ],
            [
                99.77,
                1710216000
            ]
        ],
        "statuses": []
    },
    {
        "id": 6917,
        "drug_name": "OZEMPIC (semaglutide)",
        "clinical_trial_id": "NCT03989232",
        "has_trial_insight_page": 0,
        "indication": "Type 2 Diabetes ",
        "label": "Approved",
        "value": "approved",
        "simplified_stage": "phase6",
        "stageid": 15,
        "stage_name": "Approved",
        "date": "2022-03-28",
        "link": "https:\/\/trends.crast.net\/ozempic-2-0-mg-is-approved-in-the-us-for-the-treatment-of-type-2-diabetes\/",
        "note": "Approved March 28, 2022. ",
        "company_entity_id": 385,
        "company_ticker": "NVO",
        "company_name": "Novo Nordisk A\/S",
        "company_price": "135.1100",
        "company_change": 3.87,
        "company_percent_change": 2.95,
        "company_optionable": 1,
        "company_number_of_shares": 4510000000,
        "price_change_sparkline": [
            [
                114.74,
                1706677200
            ],
            [
                115.79,
                1706763600
            ],
            [
                113.7,
                1706850000
            ],
            [
                118.26,
                1707109200
            ],
            [
                117.61,
                1707195600
            ],
            [
                118.66,
                1707282000
            ],
            [
                118.39,
                1707368400
            ],
            [
                121.2,
                1707454800
            ],
            [
                120.53,
                1707714000
            ],
            [
                119.99,
                1707800400
            ],
            [
                123.29,
                1707886800
            ],
            [
                121.75,
                1707973200
            ],
            [
                124.01,
                1708059600
            ],
            [
                121.45,
                1708405200
            ],
            [
                120.93,
                1708491600
            ],
            [
                124.52,
                1708578000
            ],
            [
                123.45,
                1708664400
            ],
            [
                123.49,
                1708923600
            ],
            [
                122.23,
                1709010000
            ],
            [
                121.54,
                1709096400
            ],
            [
                119.77,
                1709182800
            ],
            [
                124.23,
                1709269200
            ],
            [
                127.95,
                1709528400
            ],
            [
                124.65,
                1709614800
            ],
            [
                124.75,
                1709701200
            ],
            [
                135.92,
                1709787600
            ],
            [
                133.07,
                1709874000
            ],
            [
                131.24,
                1710129600
            ],
            [
                135.11,
                1710216000
            ]
        ],
        "statuses": []
    }
]